Hjem › Hodgkins lymfom › Texas
Kliniske studier for Hodgkins lymfom i Texas
15 studier for Hodgkins lymfom søker deltakere på steder i Texas.
Byer i Texas
Offisiell studietekst (engelsk)
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
RekruttererFase 1
Alder 12 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06176690CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
RekruttererFase 1
Alder 12 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT02917083Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RekruttererObservasjonsstudie
Alder 0 til 38 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06131801A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05615636Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Sarah Cannon Research Institute at St. David's South Austin, Austin
RekruttererFase 1
Alder 18 til 100 · Alle kjønn · Oppdatert 15. sep. 2026 · NCT05798897AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Houston
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06137144Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
- The University of Texas M. D. Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 til 75 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07444632Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
- UT MD Anderson, Houston
RekruttererFase 2
Alder 2 til 21 · Alle kjønn · Oppdatert 31. aug. 2026 · NCT07551583Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 12 til 80 · Alle kjønn · Oppdatert 7. aug. 2026 · NCT05092451Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 15 til 80 · Alle kjønn · Oppdatert 30. jul. 2026 · NCT02727803A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
- Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
- og 5 flere
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- og 1 flere
RekruttererFase 1
Alle aldre · Alle kjønn · Oppdatert 25. jun. 2026 · NCT04664179A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
- MD Anderson Cancer Center, Houston
RekruttererFase 2Frivillige helsepersonell ønskes velkommen
Alder 1 og eldre · Alle kjønn · Oppdatert 18. mai 2026 · NCT05355051Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
RekruttererFase 1
Alle aldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT01555892Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
RekruttererFase 1
Alder 1 til 21 · Alle kjønn · Oppdatert 6. des. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.